论文部分内容阅读
目的探讨布地奈德联合特布他林雾化吸入治疗支气管哮喘的临床疗效。方法选取2012年1月—2015年1月吉安市第一人民医院收治的120例支气管哮喘患者,分为观察组和对照组,各60例。对照组患者给予特布他林雾化治疗,观察组患者给予布地奈德联合特布他林雾化吸入治疗。比较两组患者的临床疗效及不良反应发生情况。结果观察组患者总有效率高于对照组,不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论布地奈德联合特布他林雾化吸入治疗支气管哮喘的临床疗效显著,安全性好,可提高患者的生活质量。
Objective To investigate the clinical efficacy of budesonide combined with terbutaline in the treatment of bronchial asthma. Methods A total of 120 patients with bronchial asthma admitted from the First People’s Hospital of Ji’an from January 2012 to January 2015 were selected and divided into observation group and control group, 60 cases each. The control group was given terbutaline nebulization and the observation group was given budesonide combined with terbutaline nebulization. The clinical efficacy and adverse reactions of the two groups were compared. Results The total effective rate of observation group was higher than that of control group, the incidence of adverse reactions was lower than that of control group, the difference was statistically significant (P <0.05). Conclusion Budesonide combined with Terbutaline nebulized bronchial asthma treatment of significant clinical efficacy, safety, and can improve the quality of life of patients.